Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited Potassium Content in Patients With Chronic Kidney Disease: A Pilot Study (SAFE-K)

April 23, 2026 updated by: Carla Maria Avesani, Karolinska Institutet

Säkerheten av en hälsosam växtbaserad Kost Med högre kaliuminnerhåll, jämfört Med en hälsosam växtbaserad Kost Med begränsat kaliuminnehåll Hos Patienter Med Kronisk Njursjukdom: En Pilotstudie

For many years, people with moderate to advanced chronic kidney disease (CKD) have been advised to limit their intake of potassium, a mineral found in many foods such as fruit, vegetables, legumes, whole grains, and nuts. The reason for this has been the risk of hyperkalemia, a condition in which the potassium level in the blood becomes too high and can be dangerous. In recent years, however, this view has been questioned. New research suggests that the link between potassium in food and high potassium levels in the blood may not be as clear as previously thought. People who follow a strict potassium-restricted diet experience a lower quality of life and less satisfaction with their dietary treatment. At the same time, they miss out on the health benefits of eating a varied and nutritious diet.

Today, many experts advocate a more individualized approach to potassium intake: instead of generally restricting potassium, the goal should be to maintain normal potassium levels in the blood, while encouraging a healthy diet. However, this message is not always clear in healthcare, and many people therefore continue to avoid potassium-rich foods altogether. The result is that they eat fewer natural ingredients and instead consume more processed and ultra-processed foods. Such foods can be more harmful, partly because they often contain potassium additives that are absorbed effectively by the body and their quantities are not reported in the nutritional label. This "hidden" potassium can contribute more to high potassium levels in the blood than the potassium that occurs naturally in plant-based foods. In addition, potassium from whole plant-based foods is absorbed more slowly, partly due to its fiber content.

Plant-based diets may also have other positive effects for people with kidney disease: they can contribute to reduced blood acidity, known as metabolic acidosis, healthier gut flora, lower levels of inflammation, and reduced phosphorus intake. Together, these factors can counteract several of the metabolic complications associated with kidney disease.

In a previous study, our research group showed that even patients with advanced kidney disease (CKD stage 4-5) and already elevated potassium levels could follow a healthy plant-based diet if they also used a potassium-binding drug (sodium zirconium cyclosilicate, SZC). This enabled them to eat more fruit, vegetables, and legumes, while also experiencing improved quality of life. The current study builds on these results and is planned as a pilot study in which patients with moderate to advanced kidney disease, but who are not yet being treated with dialysis, are assigned to two different dietary strategies for six months:

  • Healthy plant-based diet (healthy-PBD): a more liberal and balanced plant-based diet without specific potassium restrictions.
  • Potassium-restricted plant-based diet (restricted-PBD): a traditional plant-based diet with restrictions on potassium-rich foods, according to current standard recommendations.

The main purpose is to investigate whether the healthy plant-based diet leads to more or more severe cases of hyperkalemia than the restricted diet. Our hypothesis is that potassium levels may increase slightly in the group with a liberal diet, but not to dangerous levels. The study will also examine secondary outcomes, such as quality of life, satisfaction with treatment, and how well patients accept the diet. In addition, taste experiences will be tested with taste strips (sweet, sour, salt, bitter and umami) before and after the intervention in both groups. If this pilot study shows that a healthier and less restrictive diet is safe, it could pave the way for a larger study investigating the long-term metabolic effects of a plant-based diet in kidney care.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The overall aim of the project is to investigate whether a liberal plant-based diet, rich in fruit, vegetables, legumes, whole grains, and nuts, can be recommended to patients with mild to advanced kidney disease without leading to hyperkalemia. Traditionally, dietary advice for chronic kidney disease (CKD) has focused on potassium restriction, which has led to reduced intake of healthy foods and thereby poorer diet quality. This project aims to challenge this view by shifting the focus from potassium content itself to overall diet quality, with a particular focus on patient-centered outcomes such as safety, quality of life, treatment satisfaction, acceptance and sensory effects (taste sensitivity).

The study addresses an important knowledge gap in current nutritional guidelines for patients with kidney disease. The latest recommendations emphasize individualization and maintaining normal potassium levels, rather than general restrictions, but this advice is based on limited evidence and has not yet been tested in longer clinical studies.

This project is therefore limited to conducting a 6-month pilot study with a randomized controlled design. The focus is primarily on safety outcomes, especially the occurrence of hyperkalemia, and secondarily on patient-reported outcomes, dietary acceptance, and taste experience. Metabolic effects are not examined in detail in this study, but the results will form the basis for a larger follow-up study with a broader focus on long-term metabolic and clinical benefits.

The project's main scientific question is whether it is safe for patients with moderate to advanced kidney disease to eat a plant-based diet without restricting potassium-rich foods. In current clinical practice, patients are advised to avoid fruits, vegetables, legumes, and nuts, despite the fact that an increasing number of studies suggest that potassium from whole plant-based foods does not necessarily lead to dangerously high potassium levels in the blood. The study defines the following outcome measures:

Primary outcome: Time to first hyperkalemia event (plasma potassium > 5.5 mmol/L). Number of hyperkalemia events in the two groups during the 22-26 weeks following randomization. Potassium as a continuous variable.

Secondary endpoints: Patient-reported endpoints, quality of life (RAND-36 questionnaire) and satisfaction with treatment. Laboratory markers: inflammation, kidney function, acid-base balance, uremic toxins, vitamin K, and gut flora-related markers. Nutrition-related factors: body composition (measured using bioelectrical impedance), anthropometry, dietary intake, and taste test (sweet, sour, salt, bitter and umami). Dietary compliance: structured questionnaire on intake and 24-hour urine collection for potassium excretion.

This study is designed as a pilot study with a parallel randomized controlled trial (RCT) design with a duration of 22-26 weeks (approximately 6 months). The study will include adult participants (age 20-85) with moderate to advanced CKD, defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m², who are not yet being treated with dialysis nor have undergone kidney transplantation. Individuals with untreated comorbidities or conditions that may affect study participation will be excluded.

Randomization and intervention

Participants will be randomly assigned in a 1:1 ratio to one of two groups:

  • Healthy plant-based diet (healthy-PBD): A liberal plant-based diet that includes fruits, vegetables, legumes, whole grains, and nuts, with no specific restrictions on potassium.
  • Potassium-restricted plant-based diet (restricted-PBD): A plant-based diet with restrictions on potassium-rich foods, which corresponds to current standard advice for patients with CKD.

Both groups will receive individually tailored dietary counselling from a dietitian at baseline and during follow-up visits. Counselling will cover portion sizes, meal composition, and strategies for adhering to the assigned diet. Participants will also receive written dietary advice and food lists.

Study procedures and visits Participants will attend study visits at baseline, 4 weeks, 12 weeks, and 22-26 weeks. The following will be performed at each visit:

  • Blood tests: plasma potassium (primary safety measure), kidney function (creatinine, eGFR), acid-base balance, inflammation markers, vitamin K and uremic toxins.
  • Urine test: 24-hour urine collection for potassium, sodium, urea, and creatinine to assess compliance with the diet.
  • Anthropometry and body composition: weight, body mass index (BMI) and bioelectrical impedance analysis.
  • Patient-reported outcomes: quality of life (RAND-36) and questionnaire on satisfaction with treatment.
  • Sensory tests: taste strips to assess thresholds for sweet, sour, salt, bitter and umami.
  • Diet compliance: structured dietary questionnaire focusing on plant-based foods and potassium-rich foods, as well as a 24-hour record about intake.

Participants are instructed to contact the study team if they experience symptoms that may indicate hyperkalemia, such as muscle weakness or palpitations. If hyperkalemia (p-potassium > 5.5 mmol/L) is detected, adequate medical treatment will be provided, and continued participation in the study will be reconsidered for safety reasons.

Data collection All laboratory analyses will be performed at accredited hospital laboratories according to standardized methods with internal and external quality control. Dietary questionnaires will be validated against urinary potassium excretion. Quality of life and satisfaction questionnaires are validated versions in Swedish. Taste strips will be used under standardized conditions.

To ensure data reliability, all study data will be collected by personnel trained in standardized procedures. Randomization will be computer-generated with concealed allocation. Data entry will be double-checked and deviations verified against source material.

Surveys and interviews The structured dietary surveys will include questions about the frequency and portion size of selected food groups, adherence to prescribed portions, and barriers to following the diet. The survey on treatment satisfaction will include questions about perceived safety, trust in dietary advice, and willingness to continue with the diet after the end of the study. The responses will be analyzed descriptively and compared between groups to identify differences in acceptance and adherence.

Time commitment for participants Each study visit is expected to take approximately 60-90 minutes and will include blood and urine sampling, anthropometry, surveys, and dietary counselling. Participants will also be asked to fill in the dietary records at home and collect 24-hour urine samples at predetermined time points.

The entire study will be conducted in Sweden. All recruitment, intervention, laboratory analyses and follow-up will take place at participating Swedish nephrology clinics.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Carla M Avesani, RD, PhD, Associate Professor
  • Phone Number: +46 725460974
  • Email: carla.avesani@ki.se

Study Locations

  • Sweden
    • Stockholm Län
      • Huddinge, Stockholm Län, Sweden, 14152
        • Karolinska Institute
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Age between 20 and 85 years
  • Chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²
  • Normal potassium levels (plasma potassium 3.5-5.3 mmol/L)
  • Not on dialysis
  • Good knowledge of Swedish

Exclusion Criteria

  • Pregnancy
  • Breastfeeding
  • Kidney transplant
  • Regular use of potassium binders at least 4 days/week (e.g. sodium zirconium cyclosilicate, patiromer or sodium polystyrene sulfonate)
  • Regular prescription of daily potassium salts (e.g. potassium chloride)
  • Planned kidney transplant
  • Planned start of dialysis within the next 6 months
  • Allergy to nuts (including peanuts)
  • Mental illness and cognitive impairment that impede understanding of dietary advice
  • Comorbidities that may affect potassium balance (e.g. adrenal insufficiency, inflammatory bowel disease, chronic diarrhoea or colostomy)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Healthy plant-based diet (healthy-PBD)
Other: Healthy plant-based diet (healthy-PBD)
Healthy plant-based diet (healthy-PBD): A liberal plant-based diet that includes fruits, vegetables, legumes, whole grains, and nuts, with no specific restrictions on potassium.
Active Comparator: Potassium-restricted plant-based diet (restricted-PBD)
Other: Potassium-restricted plant-based diet
Potassium-restricted plant-based diet (restricted-PBD): A plant-based diet with restrictions on potassium-rich foods, which corresponds to current standard advice for patients with CKD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of hyperkalemia (plasma potassium >5.5 mmol/L) events in the two groups
Time Frame: for 26 weeks following randomization
Hyperkalemia is defined as plasma potassium > 5.5 mmol/L. The number of hyperkalemia events, as well as the time to the event, will be registered.
for 26 weeks following randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life (RAND-36 questionnaire - score 0 to 100)
Time Frame: for 26 weeks following randomization
Validated for patients with CKD in Sweden - Higher scores reperesent better quality of life
for 26 weeks following randomization
Renal Treatment Satisfaction Questionnaire - score 0 to 6
Time Frame: for 26 weeks following randomization
Validated for patients with CKD in Sweden. Comprised of 13 items, each item is scored by the patient from 0 to 6. The higher the score, the higher the satisfaction with the treatment.
for 26 weeks following randomization
C-reactive protein (mg/L)
Time Frame: for 26 weeks following randomization
C-reactive protein (mg/L) assessed as a continuous variable
for 26 weeks following randomization
Interleukin 6 (pg/mL)
Time Frame: for 26 weeks following randomization
Interleukin 6 (pg/mL) assessed as continous variable
for 26 weeks following randomization
Glomerular filtration rate (ml/min/1.73 m2)
Time Frame: for 26 weeks following randomization
Assessed by the Malmö-Lund equation, using serum creatinine (μmmol/L)
for 26 weeks following randomization
Albumin/creatinine ratio (spot urine) (mg/g)
Time Frame: for 26 weeks following randomization
Albumin/creatinine ratio (spot urine)
for 26 weeks following randomization
24-hour urinary creatinine excretion (mg/L)
Time Frame: for 26 weeks following randomization
24-hour urinary creatinine excretion
for 26 weeks following randomization
Serum creatinine (µmol/L)
Time Frame: for 26 weeks following randomization
Serum creatinine (µmol/L)
for 26 weeks following randomization
Plasma carbon dioxide (mmol/L)
Time Frame: for 26 weeks following randomization
Plasma carbon dioxide (mmol/L)
for 26 weeks following randomization
Plasma Trimethylamine N-oxide (TMAO) (ng/mL)
Time Frame: for 26 weeks following randomization
Trimethylamine N-oxide (TMAO) (ng/mL)
for 26 weeks following randomization
Plasma p-Cresyl sulfate (ng/mL)
Time Frame: for 26 weeks following randomization
p-Cresyl sulfate (ng/mL)
for 26 weeks following randomization
Plasma Indoxyl sulfate (ng/mL)
Time Frame: for 26 weeks following randomization
Indoxyl sulfate (ng/mL)
for 26 weeks following randomization
Vitamin K
Time Frame: for 26 weeks following randomization
dp-ucMGP (pmol/L)
for 26 weeks following randomization
Blood DNA microbial
Time Frame: for 26 weeks following randomization
Biomarkers linked to the gut microbiota measured in blood samples
for 26 weeks following randomization
Lean body mass (kg)
Time Frame: for 26 weeks following randomization
Assessed by Bioelectrical impedance
for 26 weeks following randomization
Body weight (kg)
Time Frame: for 26 weeks following randomization
Assessed with an electronic scale
for 26 weeks following randomization
Potassium intake (mg/day)
Time Frame: for 26 weeks following randomization
Assessed by 24 hour food recall
for 26 weeks following randomization
Taste perception of salt (scale 1 to 4)
Time Frame: for 26 weeks following randomization
It will be assessed by taste strips (salt). A higher score denotes higher perception.
for 26 weeks following randomization
Dietary compliance
Time Frame: for 26 weeks following randomization
Structured questionnaire on intake
for 26 weeks following randomization
24-hour potassium excretion in urine (mmol/day)
Time Frame: for 26 weeks following randomization
Will be used to assess dietary compliance to the intake of potassium
for 26 weeks following randomization
Plasma potassium as a continuous variable
Time Frame: 26 weeks following the randomization
Changes in plasma potassium (mmol/L) will be followed in both groups.
26 weeks following the randomization
Height (cm)
Time Frame: 26 weeks after the randomization
Assessed with a stadiometer in cm
26 weeks after the randomization
Taste perception of sweet (scale 1 to 4)
Time Frame: 26 weeks after the randomization
Assessed by taste strips (sweet). A higher score denotes higher perception.
26 weeks after the randomization
Taste perception to sour (scale 1 to 4)
Time Frame: 26 weeks followed the randomization
Assessed by taste strips (sour). A higher score denotes higher perception.
26 weeks followed the randomization
Taste perception of bitter (scale 1 to 4)
Time Frame: 26 weeks followed the randomization
Assessed by taste strips (bitter). A higher score denotes higher perception.
26 weeks followed the randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 10, 2026

Primary Completion (Estimated)

December 30, 2029

Study Completion (Estimated)

June 30, 2030

Study Registration Dates

First Submitted

March 9, 2026

First Submitted That Met QC Criteria

March 20, 2026

First Posted (Actual)

March 27, 2026

Study Record Updates

Last Update Posted (Actual)

April 29, 2026

Last Update Submitted That Met QC Criteria

April 23, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-06661-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

We can share upon requirement and justification on the purpose for sharing the data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperkalemia

Clinical Trials on Healthy plant-based diet (healthy-PBD)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe